- Sales rose 11% (core sales flat); net income fell 8% to $73M and EPS was $1.12 (adjusted $1.19, -8% constant currency).
- Adjusted EBITDA margin dropped to 2% from 20.7% year‑over‑year.
- Returned $131M to shareholders via share repurchases and dividends.
- Demand cited in GLP‑1 therapies, biologics, systemic nasal drug delivery and nasal decongestants; injectables posted double‑digit growth.
Quarterly financials
For the quarter ended March 31, 2026, reported sales rose 11% while core sales were flat; reported net income declined 8% to $73 million and reported EPS fell 4% to $1.12, with adjusted EPS of $1.19 (down 8% at constant currency).
Profitability and capital returns
Adjusted EBITDA margin compressed to 2% from 20.7% year‑over‑year; the company returned $131 million to shareholders through share repurchases and dividends.
Business trends
Results were affected by emergency medicine destocking and a particularly strong prior‑year prescription quarter; injectables delivered another quarter of strong double‑digit growth, and consumer dispensing posted volume growth in Beauty and Closures driven by prestige fragrance and beverage applications.
Pharma demand drivers and leadership
Management cited growing demand in GLP‑1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing and active material solutions; Gael Touya was named Aptar’s next CEO effective September 1, 2026.
